Divi's Laboratories Market Cap Crosses Rs 3 Lakh Crore: What Is Driving The Rally
Divi's Laboratories set out an expansion in a quarterly results development.
· NDTV Profit
Divi’s Laboratories entered the Rs 3 lakh crore market capitalisation club after a strong stock rally, backed by 35% revenue growth, expanding margins, and optimism around its custom synthesis…
The analysis
Divi's Laboratories reported Rs 3 Lakh Crore, with movement of 35% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +12.1% on the day at ₹11,565.50, and has returned +38.5% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved +3.3% over the same period, so Divi's Laboratories is running 35.2 points ahead of its peers.
For Divi's Laboratories, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Divi's Laboratories (DIVISLAB), in Pharma & Healthcare.
- Over three months: Divi's Laboratories +38.5% against Pharma & Healthcare +3.3% (35.2 points ahead).
- Trading well above normal today: Divi's Laboratories at 3.2 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Divi's LaboratoriesDIVISLAB · Pharma & Healthcare | ₹11,565.50 | +12.1% | +23.8% | +38.5% | 0.0% | 3.2× | — |
Pharma & Healthcare
1M +7.9% · 3M +3.3%
Divi's Laboratories
Prices as of 9 Nov 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Divi's Labs Q2 result: Net profit rises 64% to ₹1,127 cr on higher revenue
ICICI Bank, Divi's among 14 NSE 500 stocks hit new highs in Muhurat session
Up 118% in 6 months! This volume shocker pharma stock skyrockets 14% despite weak trends on Dalal Street Do you own?
Muhurat Trading LIVE: GIFT Nifty signals muted open; Tata Steel, Divi's Labs shares in focus
Muhurat Trading 2026: Tata Steel, Sun Pharma, BSE among top gainers as Nifty 50, Sensex swing between gains and losses